Objective: CT remains the imaging modality of choice in the diagnosis of colorectal cancer (CRC) and anal cancer. However, advances in imaging have expanded the role of MRI and PET/CT. This article focuses on the evolving role of FDG PET/CT in the diagnosis, radiation therapy planning, therapy assessment, and posttherapy monitoring of CRC and anal cancer.
Conclusion: FDG PET/CT is a valuable imaging modality that impacts the clinical management of patients with CRC and those with anal cancer.
Keywords: PET/CT; anal cancer; colorectal cancer; radiation therapy planning; therapy assessment.